Structural equation modeling identifies differential links of pathologies and 
atrophy in dementia

Haag, L; Lancini, I; Yakupov, R; Ziegler, G; Yi, Y-J; Wenzel, G; Lüsenbrink, F; Peters, O; Spruth, E; Altenstein, S; Priller, J; Schneider, L-S; Wang, X; Preis, L; Brosseron, F; Roy-Kluth, N; Schneider, A; Fliessbach, K; Wagner, M; Wolfsgruber, S; Wiltfang, J; Hansen, N; Rostamzadeh, A; Ewers, M; Buerger, K; Perneczky, R; Janowitz, D; Rauchmann, B-S; Teipel, S; Kilimann, I; Goerss, D; Laske, C; Munk, M; Heneka, P; Dechent, M; Hetzer, S; Scheffler, K; Düzel, E; Betts, M; Hämmerer, D

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

ポスター

Structural equation modeling identifies differential links of pathologies and atrophy in dementia

MPS-Authors

/persons/resource/persons84187

Scheffler, K
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

https://ww6.aievolution.com/hbm2401/index.cfm?do=abs.viewAbstract&style=1&abstractID=2932
(要旨)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Haag, L., Lancini, I., Yakupov, R., Ziegler, G., Yi, Y.-J., Wenzel, G., Lüsenbrink, F., Peters, O., Spruth, E., Altenstein, S., Priller, J., Schneider, L.-S., Wang, X., Preis, L., Brosseron, F., Roy-Kluth, N., Schneider, A., Fliessbach, K., Wagner, M., Wolfsgruber, S., Wiltfang, J., Hansen, N., Rostamzadeh, A., Ewers, M., Buerger, K., Perneczky, R., Janowitz, D., Rauchmann, B.-S., Teipel, S., Kilimann, I., Goerss, D., Laske, C., Munk, M., Heneka, P., Dechent, M., Hetzer, S., Scheffler, K., Düzel, E., Betts, M., & Hämmerer, D. (2024). Structural equation modeling identifies differential links of pathologies and atrophy in dementia. Poster presented at 30th Annual Meeting of the Organization for Human Brain Mapping (OHBM 2024), Seoul, South Korea.

引用: https://hdl.handle.net/21.11116/0000-000F-5176-1

要旨

Introduction:
Our main source of noradrenaline in the cortex is the locus coeruleus, a brainstem nucleus which is amongst the brain structures affected earliest by Alzheimer's disease-related tau pathology (Braak et al., 2011). Since intact noradrenergic modulation has been linked to cognitive reserve in ageing (Wilson et al., 2013), interindividual differences in the integrity of cortical noradrenaline-projection regions could be an important neural resource for cognitive reserve in ageing. The aim of this study was to determine whether volumes of brain areas known to be rich in noradrenergic receptors and transporters are relatively preserved in individuals with lower levels of Alzheimer's disease pathology.
Methods:
Based on prior work on NA receptor and transporter distribution (Palomero-Gallagher et al., 2015), we distinguished between 'areas high in noradrenaline' and 'areas low in noradrenaline' and compared differential associations of atrophy in those areas with CSF amyloid-ß 42/40, CSF phosphorylated tau protein, and memory function across healthy controls (n = 122), subjects with subjective cognitive decline (n = 156) and patients with mild cognitive impairment or mild Alzheimer's disease dementia (n = 126). Analyses were carried out with structural equation modeling which allows to assess the interrelations between multiple variables while testing for group differences in these interrelations.
Results:
Our analyses confirmed that regional brain volumes in 'areas high in NA' vs. 'areas low in NA' are differentially related to AD pathology markers. Only 'areas high in noradrenaline' were related to disease markers. Across all groups, atrophy in 'areas high in noradrenaline' were linked to worse memory. Moreover, groups differed in their links between atrophy in 'areas high in noradrenaline' and amyloid levels or memory capacity. In subjects with subjective cognitive decline, higher amyloid pathology predicted atrophy in 'areas high in noradrenaline' (ß = 0.343), while in patients with mild cognitive impairment and Alzheimer's disease, higher amyloid pathology was associated with memory impairment (ß = 0.295). The study also found that CSF amyloid and tau biomarkers were less correlated in the subjective cognitive decline (ß = -0.366) as compared to the mild cognitive impairment/Alzheimer's disease groups (ß = -0.424), suggesting distinguishable interrelatedness of amyloid and tau after early disease onset.